Overview

tyrosine kinase inhibitor


'tyrosine kinase inhibitor' can also refer to...

tyrosine kinase inhibitor

tyrosine kinase inhibitor

Skin problems and EGFR-tyrosine kinase inhibitor

Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine

Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors

Tyrosine Kinase Inhibitor Research Presses on Despite Halted Clinical Trial

Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase

Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model

Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib

About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?

Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer

Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib

plenary session 4: inhibitors of growth factor receptors and their tyrosine kinases

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

Tannic Acid, a Potent Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase

Twelfth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Tyrosine Kinase Inhibitors

Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids

The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth

 

More Like This

Show all results sharing this subject:

  • Medicine and Health

GO

Show Summary Details

Quick Reference

Any one of a class of drugs that interfere with cell growth in a variety of different ways by inhibiting the action of tyrosine kinases. This family of enzymes, which occur both within cells and as components of cell-membrane receptor sites, have an important role in cell division and cell growth. Many tumour cells have been shown to have both intracellular enzymes and extracellular receptor sites, and a variety of anticancer agents have been developed to inhibit enzyme activity at these sites. Among these drugs are imatinib, dasatinib (Sprycel), and nilotinib (Tasigna), used for treating chronic myeloid leukaemia; sunitinib, for treating renal cell carcinoma; and erlotinib (Tarceva), for treating pancreatic cancer and non-small-cell lung cancer. See also epidermal growth factor receptor.

Subjects: Medicine and Health.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.